AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2676343 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone infusion
Number of subjects: 22
Study 2676343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 332349 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic combination chemotherapy (50 patients)
Number of subjects: 99
Study 332349 — intervention group
Group type: COMPARATOR
Intervention: Extensive 'systemic' radiotherapy (49 patients)
Number of subjects: 99
Study 332349 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic combination chemotherapy with total‐body irradiation (34 patients)
Number of subjects: 99
Study 332349 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy (34 patients)
Number of subjects: 99
Study 30458655 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrulline Malate (CM) 8 g (1.1:1 ratio)
Number of subjects: 19
Study 30458655 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6 g citric acid)
Number of subjects: 19
Study 31414632 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct microscopy, culture, and PCR methods for diagnosing Blastocystis spp.
Number of subjects: 100
Study 31414632 — intervention group
Group type: EXPERIMENTAL
Intervention: SSU rRNA gene sequencing and STS-PCR methods for subtype distribution analysis.
Number of subjects: 100
Study 31414632 — intervention group
Group type: COMPARATOR
Intervention: Comparison of demographic characteristics and clinical findings between positive and negative cases.
Number of subjects: 100
Study 31414632 — intervention group
Group type: COMPARATOR
Intervention: Comparison of symptoms and subtypes of Blastocystis spp.
Number of subjects: 100
Study 29074509 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 102
Study 27137716 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxegol 25mg
Number of subjects: 32
Study 27137716 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxegol 60mg
Number of subjects: 32
Study 27137716 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxegol 125mg
Number of subjects: 32
Study 27137716 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxegol 250mg
Number of subjects: 32
Study 27137716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 23620319 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonographically guided blocks
Number of subjects: 415
Study 23620319 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulator guided blocks
Number of subjects: 415
Study 21445665 — intervention group
Group type: EXPERIMENTAL
Intervention: Guitar timbre exposure
Number of subjects: 0
Study 21445665 — intervention group
Group type: EXPERIMENTAL
Intervention: Marimba timbre exposure
Number of subjects: 0
Study 19361802 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact
Number of subjects: 100
Study 19361802 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study 16287900 — intervention group
Group type: COMPARATOR
Intervention: Standard laryngoscope
Number of subjects: 32
Study 16287900 — intervention group
Group type: COMPARATOR
Intervention: Disposable laryngoscope
Number of subjects: 32
Study 16287900 — intervention group
Group type: COMPARATOR
Intervention: Covered laryngoscope
Number of subjects: 32
Study 16287900 — intervention group
Group type: EXPERIMENTAL
Intervention: Covered laryngoscope vs Disposable laryngoscope
Number of subjects: 32
Study 15163505 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent aluminum-adjuvanted whole virus formulations with 1.9 microg HA per dose
Number of subjects: 200
Study 15163505 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent aluminum-adjuvanted whole virus formulations with 3.75 microg HA per dose
Number of subjects: 200
Study 15163505 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent aluminum-adjuvanted whole virus formulations with 7.5 microg HA per dose
Number of subjects: 200
Study 15163505 — intervention group
Group type: COMPARATOR
Intervention: Split virus vaccine (15 microg HA per dose) without aluminum adjuvantation
Number of subjects: 200
Study 11060830 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanoteplase (120 KU/kg)
Number of subjects: 0
Study 11060830 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanoteplase
Number of subjects: 0
Study 9059244 — intervention group
Group type: EXPERIMENTAL
Intervention: SLO microperimetry for detecting deep and relative scotomas in full thickness macular holes
Number of subjects: 106
Study 9059244 — intervention group
Group type: COMPARATOR
Intervention: SLO microperimetry for detecting deep and relative scotomas in macular pseudoholes or impending macular holes
Number of subjects: 106
Study 8492160 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling with normal, phasic ankle activity (free-form cycling)
Number of subjects: 0
Study 8492160 — intervention group
Group type: COMPARATOR
Intervention: Static limb positioning with consistent SOL activity
Number of subjects: 0
Study 8492160 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled TA cycling activity conditions
Number of subjects: 0
Study 8492160 — intervention group
Group type: COMPARATOR
Intervention: Static limb positioning
Number of subjects: 0
Study 2891739 — intervention group
Group type: EXPERIMENTAL
Intervention: Metipranolol 0.1%
Number of subjects: 45
Study 2891739 — intervention group
Group type: EXPERIMENTAL
Intervention: Metipranolol 0.3%
Number of subjects: 45
Study 2891739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 29189291 — intervention group
Group type: COMPARATOR
Intervention: Epidural bupivacaine 0.125%
Number of subjects: 36
Study 29189291 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine 0.2%
Number of subjects: 36
Study 27125948 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy
Number of subjects: 10732
Study 27125948 — intervention group
Group type: COMPARATOR
Intervention: PCI alone
Number of subjects: 10732
Study 23628627 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-body BFR intervention (occlusion cuff inflated to 180 mmHg)
Number of subjects: 20
Study 22337508 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐Behaviour Therapy (CBT)
Number of subjects: 0
Study 22337508 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 0
Study 22337508 — intervention group
Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 0
Study 19430819 — intervention group
Group type: EXPERIMENTAL
Intervention: GP-led follow-up
Number of subjects: 18
Study 18243585 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month methadone maintenance with minimal counseling
Number of subjects: 0
Study 18243585 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month methadone maintenance with standard counseling
Number of subjects: 0
Study 18243585 — intervention group
Group type: COMPARATOR
Intervention: 21-day methadone detoxification
Number of subjects: 0
Study 15934094 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (500 mg/day)
Number of subjects: 184
Study 15934094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study 14615670 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective treatment of GERD with prolonged and aggressive antisecretory therapy
Number of subjects: 0
Study 10387955 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen with organic acids as excipients in enteric matrix granules (Eudragit S and Aqoat AS-HF)
Number of subjects: 0
Study 10387955 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioavailability tests
Number of subjects: 0
Study 10387955 — intervention group
Group type: EXPERIMENTAL
Intervention: Mathematical transformation of data for individual formulations
Number of subjects: 0
Study 8697164 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha
Number of subjects: 38
Study 8697164 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymomodulin
Number of subjects: 38
Study 8697164 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 38
Study 8697164 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha and Thymomodulin
Number of subjects: 38
Study 2053717 — intervention group
Group type: EXPERIMENTAL
Intervention: In-service lectures for 30% of nurses and opinion leaders' tutorials for all nurses in group A
Number of subjects: 30
Study 2053717 — intervention group
Group type: EXPERIMENTAL
Intervention: Opinion leaders' tutorials alone in group B
Number of subjects: 30
Study 2053717 — intervention group
Group type: COMPARATOR
Intervention: Lectures alone in group C
Number of subjects: 30
Study 2053717 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct observation practices in group A
Number of subjects: 30
Study 2053717 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct observation practices in group B
Number of subjects: 30
Study 7201812 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoretard (350 mg theophylline in capsule)
Number of subjects: 7
Study 30630772 — intervention group
Group type: EXPERIMENTAL
Intervention: R-MBVP (methotrexate-based chemotherapy with rituximab)
Number of subjects: 200
Study 30630772 — intervention group
Group type: COMPARATOR
Intervention: MBVP (methotrexate-based chemotherapy without rituximab)
Number of subjects: 200
Study 30630772 — intervention group
Group type: COMPARATOR
Intervention: MBVP (control group)
Number of subjects: 200
Study 30630772 — intervention group
Group type: EXPERIMENTAL
Intervention: R-MBVP (intervention group)
Number of subjects: 200
Study 29214526 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 30
Study 27199494 — intervention group
Group type: EXPERIMENTAL
Intervention: R-T estimation using CoaguChek XS
Number of subjects: 0
Study 24690402 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured educational group programme incorporating psychological approaches
Number of subjects: 362
Study 24690402 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured educational group programme
Number of subjects: 362
Study 22350624 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel pre-treatment within 5 days prior to surgery
Number of subjects: 596
Study 22350624 — intervention group
Group type: COMPARATOR
Intervention: No clopidogrel
Number of subjects: 596
Study 19055871 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-mediated cognitive behavioural counselling plus exercise (GMCB)
Number of subjects: 57
Study 19055871 — intervention group
Group type: COMPARATOR
Intervention: Standard exercise (SE)
Number of subjects: 57
Study 17173912 — intervention group
Group type: EXPERIMENTAL
Intervention: RF-NaP (40 tablets, split dosing, 3 every 15 minutes)
Number of subjects: 34
Study 17173912 — intervention group
Group type: EXPERIMENTAL
Intervention: RF-NaP (32 tablets, split dosing, 4 every 15 minutes)
Number of subjects: 34
Study 17173912 — intervention group
Group type: EXPERIMENTAL
Intervention: RF-NaP (28 tablets, split dosing, 4 every 15 minutes)
Number of subjects: 34
Study 17173912 — intervention group
Group type: EXPERIMENTAL
Intervention: RF-NaP (32 tablets, evening-only dosing, 4 every 15 minutes)
Number of subjects: 34
Study 17173912 — intervention group
Group type: EXPERIMENTAL
Intervention: RF-NaP (28 tablets, evening-only dosing, 4 every 15 minutes)
Number of subjects: 34
Study 17173912 — intervention group
Group type: COMPARATOR
Intervention: Visicol (40 tablets, split dosing, 3 every 15 minutes)
Number of subjects: 34
Study 15179409 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose hyperforin-rich extract LI 160
Number of subjects: 96
Study 15179409 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g Hypericum powder with comparable hyperforin content
Number of subjects: 96
Study 15179409 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g Hypericum powder with half the hyperforin content
Number of subjects: 96
Study 15179409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 15179409 — intervention group
Group type: COMPARATOR
Intervention: 2 g powder without hyperforin, tea, juice, oil extract, hyperforin-free extract (Ze 117), low daily doses of hyperforin-containing Hypericum powder (1 g, 0.5 g)
Number of subjects: 96
Study 11472387 — intervention group
Group type: EXPERIMENTAL
Intervention: Metamizol 0.5 g
Number of subjects: 417
Study 11472387 — intervention group
Group type: EXPERIMENTAL
Intervention: Metamizol 1 g
Number of subjects: 417
Study 11472387 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid 1 g
Number of subjects: 417
Study 11472387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 417
Study 9684781 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic test for rapid screening of mutations G2811A (R854Q), C2696T (R816W), T2701A (H817Q), and G2823T (C858F) using polymerase chain reaction (PCR).
Number of subjects: 108
Study 9684781 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic test for rapid screening of mutations G2811A (R854Q), C2696T (R816W), T2701A (H817Q), and G2823T (C858F).
Number of subjects: 108
Study 7850823 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma BNP measurement
Number of subjects: 24
Study 3382333 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression screw and plate fixation
Number of subjects: 201
Study 3382333 — intervention group
Group type: COMPARATOR
Intervention: Ender's nails
Number of subjects: 201
Study 29602986 — intervention group
Group type: EXPERIMENTAL
Intervention: Appendectomy training on the virtual reality simulator until proficiency, followed by cholecystectomy tasks.
Number of subjects: 44
Study 29602986 — intervention group
Group type: COMPARATOR
Intervention: Directly started with cholecystectomy tasks on the virtual reality simulator.
Number of subjects: 44
Study 29602986 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups underwent proficiency-based basic training.
Number of subjects: 44
Study 26792707 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Integrated Movement Enhancement (DIME) injury prevention program
Number of subjects: 1104
Study 26792707 — intervention group
Group type: COMPARATOR
Intervention: Standard Warm-Up (SWU) program
Number of subjects: 1104
Study 24615085 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy
Number of subjects: 57
Study 24615085 — intervention group
Group type: COMPARATOR
Intervention: Partial tonsillectomy
Number of subjects: 57
Study 24615085 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 57
Study 23545707 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan 100 mg daily
Number of subjects: 169
Study 23545707 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 169
Study 21490284 — intervention group
Group type: EXPERIMENTAL
Intervention: Endpoint visual feedback
Number of subjects: 0
Study 21490284 — intervention group
Group type: EXPERIMENTAL
Intervention: No endpoint visual feedback
Number of subjects: 0
Study 18722039 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide (CP10)
Number of subjects: 92
Study 18722039 — intervention group
Group type: EXPERIMENTAL
Intervention: 16% carbamide peroxide (CP16)
Number of subjects: 92
Study 18722039 — intervention group
Group type: COMPARATOR
Intervention: Control group not applicable
Number of subjects: 92
Study 16432441 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 12
Study 16432441 — intervention group
Group type: COMPARATOR
Intervention: Comparison conditions (routine care or another treatment)
Number of subjects: 12
Study 14640848 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of processing fluency in artificial grammar learning tasks (Experiments 1, 2, 4, and 7)
Number of subjects: 0
Study 14640848 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluency manipulation in recognition tasks (Experiments 4-6)
Number of subjects: 0
Study 14640848 — intervention group
Group type: COMPARATOR
Intervention: Control condition in classification tasks (Experiment 7)
Number of subjects: 0
Study 14640848 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition decisions under identical conditions (Experiments 3 and 5)
Number of subjects: 0
Study 11081322 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (3 x 20 mg/day for 24 hours prior to exercise test)
Number of subjects: 16
Study 11081322 — intervention group
Group type: COMPARATOR
Intervention: Control group (no drug administered)
Number of subjects: 16
Study 9121852 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 600 mu g twice daily
Number of subjects: 20
Study 9121852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1537130 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimobendan 5 mg/day
Number of subjects: 198
Study 1537130 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimobendan 10 mg/day
Number of subjects: 198
Study 1537130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 1537130 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimobendan (all doses combined)
Number of subjects: 198
Study 6714792 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclotropium bromide (60 mg)
Number of subjects: 24
Study 6714792 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine N-butylbromide (60 mg)
Number of subjects: 24
Study 6714792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30426714 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosaprepitant
Number of subjects: 163
Study 30426714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 29327602 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) with gallium-aluminum-arsenide laser at 850 nm wavelength for 10 sessions, 3 times a week.
Number of subjects: 66
Study 29327602 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) with 2000 shock waves at 0.02 mJ/mm2 for 3 sessions, once a week.
Number of subjects: 66
Study 29327602 — intervention group
Group type: COMPARATOR
Intervention: Usual care (exercises and orthotic supports) only.
Number of subjects: 66
Study 26823210 — intervention group
Group type: EXPERIMENTAL
Intervention: FF 100 μg in the morning (AM)
Number of subjects: 28
Study 26823210 — intervention group
Group type: EXPERIMENTAL
Intervention: FF 100 μg in the evening (PM)
Number of subjects: 28
Study 26823210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 24288077 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine lateral retinacular release
Number of subjects: 148
Study 24288077 — intervention group
Group type: COMPARATOR
Intervention: No lateral retinacular release (Control)
Number of subjects: 148
Study 21715124 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDIAS 2 ICT
Number of subjects: 186
Study 21715124 — intervention group
Group type: COMPARATOR
Intervention: ACC (established education programme)
Number of subjects: 186
Study 21040188 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow up-titration with paroxetine (increments of 2.5 mg/day every 2 days)
Number of subjects: 60
Study 21040188 — intervention group
Group type: COMPARATOR
Intervention: Standard up-titration with paroxetine (increments of 10 mg/day every week)
Number of subjects: 60
Study 18949779 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil in combination with prednisone
Number of subjects: 0
Study 16288373 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-6 L2E7 vaccine with AS02A adjuvant
Number of subjects: 320
Study 16288373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study 11923135 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant postoperative chemoradiotherapy
Number of subjects: 553
Study 11923135 — intervention group
Group type: EXPERIMENTAL
Intervention: D0 lymphadenectomy
Number of subjects: 553
Study 11923135 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment variation
Number of subjects: 553
Study 11923135 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox multivariate regression analysis
Number of subjects: 553
Study 9790393 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 3689
Study 9790393 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal glucose tolerance
Number of subjects: 3689
Study 9790393 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational diabetes mellitus
Number of subjects: 3689
Study 9790393 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma glucose level 1 hour after a 50-g oral glucose challenge
Number of subjects: 3689
Study 8543750 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow's milk-based formula
Number of subjects: 20
Study 8543750 — intervention group
Group type: COMPARATOR
Intervention: Casein hydrolysate formula
Number of subjects: 20
Study 2242080 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal insulin application
Number of subjects: 6
Study 2242080 — intervention group
Group type: COMPARATOR
Intervention: Sulfonylurea monotherapy
Number of subjects: 6
Study 98196 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide (up to 20 mg daily)
Number of subjects: 0
Study 98196 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine (up to 1,000 mg daily)
Number of subjects: 0
Study 29676140 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenqi Dihuang decoction
Number of subjects: 205
Study 28272808 — intervention group
Group type: EXPERIMENTAL
Intervention: CardioMEMS HF System
Number of subjects: 0
Study 28272808 — intervention group
Group type: COMPARATOR
Intervention: Standard of care treatment for HF
Number of subjects: 0
Study 26275648 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyherbal formulation (PHF) 500 mg/day, up titrated to 3 g/day
Number of subjects: 93
Study 26275648 — intervention group
Group type: COMPARATOR
Intervention: Metformin 500 mg/day, up titrated to 2 g/day
Number of subjects: 93
Study 26275648 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyherbal formulation (PHF)
Number of subjects: 93
Study 26275648 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 93
Study 23811465 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal medicine treatment
Number of subjects: 15
Study 23811465 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 15
Study 21073734 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional treatment (early active motion within the limits of pain)
Number of subjects: 100